OpenNashPodcasts

Topic

Merck

Merck is a drug company that comes up in podcasts about biotech, cancer treatments, drug discovery and clinical trials. Speakers discussed its melanoma partnership with Moderna, its use of AI, and how it runs its trials.

Stéphane Bancel told a16z's Raising Health that Moderna and Merck hope to have their melanoma treatment available to patients in 2027. Ben Comer said on Business Of Biotech that Merck invested nearly $18 billion in research and development in 2024. Jennifer Sheller said she has been at Merck for over eight years and described its acquisitions of Peloton Therapeutics and Acceleron.

28 facts from 8 episodes, in date order. These are what speakers said on the shows, each linked to the moment it was said. They aren't independently verified.

1990s

In the late 1990s, clinical research associates verified hospital records against handwritten triple-copy NCR paper forms, which later gave way to electronic data capture.

“when I first started in the late 90s, it was, you know, triple NCR paper. So we'd go out to the hospitals to make sure that the records in the hospital system matched what was handwritten on an NCR form.”

Jennifer Sheller · Modernizing Clinical Trial Operations With Merck's Jennifer Sheller, 0:05:12

2015

According to Bancel, the individualized cancer treatment technology emerged from Moderna's labs around 2015-2016, when Moderna partnered with Merck.

“a technology that emerged from Moderna Labs back in 2015, 2016 when we did a partnership with Merck as we were looking for one of the best companies in immunotherapy to partner”

Stéphane Bancel · Moderna CEO Stéphane Bancel on the Next Era of mRNA, 0:08:25

2026

Bancel said the Moderna and Merck Phase 3 melanoma trial also met its secondary endpoint of distant metastasis-free survival at the first interim analysis.

“we met the secondary endpoint which was distant metastasis-free survival which is of course takes more time to mature”

Stéphane Bancel · Moderna CEO Stéphane Bancel on the Next Era of mRNA, 0:05:01

2027

Bancel said Moderna and Merck hope to have the melanoma treatment available to patients in 2027 and that the factory in Massachusetts is ready.

“we hope in 2027 and then we're going to try to make it as fast as we can The factory is ready in Massachusetts”

Stéphane Bancel · Moderna CEO Stéphane Bancel on the Next Era of mRNA, 0:06:24

Undated

Luke Timmerman notes that Merck launched Gardasil and Pfizer-Wyeth launched Prevnar, two commercially successful vaccines, before Clark joined Genocea.

“Merck had come out with Gardasil and Pfizer-Wyeth had come out with Prevnar.”

Luke Timmerman · Ep19: Chip Clark, 0:25:07

Undated

Sheller spent about 13 years at Sanofi, then moved to the biotech Kyowa Kirin, and has now been at Merck for over eight years.

“I spent about 13 years at large pharma at Sanofi and went to a small biotech, Keowakirin, shortly thereafter, before coming back into large pharma here at Merck for over eight years.”

Jennifer Sheller · Modernizing Clinical Trial Operations With Merck's Jennifer Sheller, 0:08:58

Undated

Merck's clinical operations model uses about 60% of its own headcount and about 40% functional service provider staff.

“So he brought everything in-house and built an operating model where we have, you know, 60% headcount through our company and then 40% or so through functional service provider.”

Jennifer Sheller · Modernizing Clinical Trial Operations With Merck's Jennifer Sheller, 0:10:35

Undated

Sheller says unit-priced outsourcing contracts fit poorly because a safety signal can require extra monitoring, forcing change orders.

“if you have unitized pricing for a given study, X number of monitoring visits, X number of phone calls to a site, that's not the real world because you might have a safety signal where you need extra monitoring.”

Jennifer Sheller · Modernizing Clinical Trial Operations With Merck's Jennifer Sheller, 0:15:14

Undated

During the Peloton integration, Sheller hired a summer intern to shadow the team and write the integration playbook that became Merck's operations standard.

“I actually hired one of my summer interns to extend her stay for a project to shadow us and build the playbook out.”

Jennifer Sheller · Modernizing Clinical Trial Operations With Merck's Jennifer Sheller, 0:21:37

Undated

Some research sites told Merck they would not run a trial unless non-physician sub-investigators, such as nurse practitioners, were allowed under the R3 changes, and Merck changed its process.

“hey, look, we're not going to do this trial unless you do apply the R3 changes and having non-physician investigators or sub-investigators in the trial.”

Jennifer Sheller · Modernizing Clinical Trial Operations With Merck's Jennifer Sheller, 0:44:11

Undated

Ghodsi said Databricks customer Merck created a model called Teddy, which stands for transformer enabled drug discovery.

“customer Merck, uh, that in the life science space created a model called Teddy. Teddy stands for transformer enabled drug discovery.”

Ali Ghodsi · AI Enterprise - Databricks & Glean | BG2 Guest Interview, 0:04:47

Undated

Ghodsi described the Teddy model as a transformer that predicts what is missing from a genome and learns the gene regulatory network, which he said helps with drug discovery.

“it instead can figure out which genome is missing if you remove a genome. So it really understands the gene regulatory network”

Ali Ghodsi · AI Enterprise - Databricks & Glean | BG2 Guest Interview, 0:05:17

Episodes